Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
01/07/18Alnylam Announces 2018 Corporate Goals
Patisiran Expected to be First Commercially Available RNAi Therapeutic in Mid-2018 Restructured Sanofi Alliance Provides Alnylam with Global Commercial Footprint for ATTR Amyloidosis Givosiran Interim Phase 3 Data Expected in Mid-2018 and U.S. New Drug Application Filing Anticipated in Late 2018 Company Plans to Advance Three Additional Phase 3 Programs: Fitusiran, Inclisiran, and ALN-TTRsc02 Company Updates ... 
Printer Friendly Version
01/07/18Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
– Restructuring Enables Streamlined Development and Optimization of Commercial Opportunities for ATTR Amyloidosis and Hemophilia Programs – – Alnylam Obtains Global Rights for Investigational ATTR Amyloidosis Programs: Patisiran and ALN-TTRsc02 – – Sanofi Obtains Global Rights for Investigational Therapeutic Fitusiran in Hemophilia and Other Rare Bleeding Disorders – – Alnylam to Host Conference Call Today, Sunday, January 7 at 4:... 
Printer Friendly Version
01/04/18Alnylam Expands Alnylam Act™ Program to Include No-Charge Third-Party Genetic Testing and Counseling for People at Risk for Acute Hepatic Porphyrias
– Individuals with Acute Hepatic Porphyrias (AHPs), a Family of Ultra-Rare Genetic Diseases, are Often Misdiagnosed and May Experience an Average Delay in Diagnosis of 15 Years – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has expanded the Alnylam Act™ program to include no-charge, third-party genetic testing and counseling for... 
Printer Friendly Version
01/02/18Alnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 8:00 am PT (11:00 am ET) at The Westin St. Francis in San Francisco. In addition, the company will webcast the Q&A breakout session immediately following its present... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.